Application of Anti-Viral Adoptive T-Cell Therapy to Primary Immunodeficiency Patients

Abstract

Viral infections cause significant morbidity and mortality in primary immunodeficiency (PID) patients with combined or cellular defects. The limited utility of antiviral medications in more substantial defects often leaves hematopoietic stem cell transplant (HSCT) as the only effective treatment, but this therapy can be limited by lack of donor or patient illness. Adoptive therapy with anti-viral cytotoxic T lymphocytes (CTLs) has reduced viral complications in cancer patients post-HSCT and we now describe the first experience with anti-viral CTLs in PID patients with and without HSCT.